OCULAR THERAPEUTIX, INC (OCUL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 6M 12M 18M Q1 '14: 27K Q2 '14: 97K Q3 '14: 143K Q4 '14: 505K Q1 '15: 426K Q2 '15: 459K Q3 '15: 429K Q4 '15: 436K Q1 '16: 458K Q2 '16: 441K Q2 '16: 441K Q3 '16: 477K Q4 '16: 511K Q1 '17: 475K Q2 '17: 438K Q3 '17: 523K Q4 '17: 487K Q1 '18: 340K Q2 '18: 648K Q3 '18: 498K Q4 '18: 504K Q1 '19: 492K Q2 '19: 650K Q3 '19: 829K Q4 '19: 2.3M Q1 '20: 2.6M Q2 '20: 1.6M Q3 '20: 5.9M Q4 '20: 7.3M Q1 '21: 7.3M Q2 '21: 11.7M Q3 '21: 12.2M Q4 '21: 12.3M Q1 '22: 13.2M Q2 '22: 12.3M Q3 '22: 12M Q4 '22: 14.1M Q1 '23: 13.4M Q2 '23: 15.2M Q3 '23: 15.1M Q4 '23: 14.8M Q1 '24: 14.8M Q2 '24: 16.4M Q3 '24: 15.4M Q4 '24: 17.1M Q1 '25: 10.7M Q2 '25: 13.5M Q3 '25: 14.5M Q4 '25: 13.2M Q1 '26: 10.8M Q2 '26: 13.5M Q2 '14 Q1 '16 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Gross Profit Quarterly

0 6M 12M 18M Q1 '18: 260K Q2 '18: 495K Q3 '18: 383K Q4 '18: 387K Q1 '19: 364K Q2 '19: 98K Q3 '19: 23K Q4 '19: 1.4M Q1 '20: 1.8M Q2 '20: 1.4M Q3 '20: 5.4M Q4 '20: 6.7M Q1 '21: 6.5M Q2 '21: 10.6M Q3 '21: 10.8M Q4 '21: 11.2M Q1 '22: 11.9M Q2 '22: 11.1M Q3 '22: 10.9M Q4 '22: 13.1M Q1 '23: 12.2M Q2 '23: 13.9M Q3 '23: 13.7M Q4 '23: 13.4M Q1 '24: 13.4M Q2 '24: 14.9M Q3 '24: 13.9M Q4 '24: 15.9M Q1 '25: 9.4M Q2 '25: 11.5M Q3 '25: 12.8M Q4 '25: 11.7M Q1 '26: 9.5M Q2 '26: 11.5M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q1 '13: -3.1M Q2 '13: -3M Q3 '13: -3.4M Q4 '13: -3.4M Q1 '14: -6.8M Q2 '14: -5.9M Q3 '14: -6.8M Q4 '14: -7.5M Q1 '15: -7.1M Q2 '15: -9.6M Q3 '15: -11.2M Q4 '15: -10.3M Q1 '16: -10.5M Q2 '16: -11.1M Q2 '16: -11.1M Q3 '16: -9.2M Q4 '16: -12.5M Q1 '17: -15.7M Q2 '17: -18.3M Q3 '17: -15.2M Q4 '17: -12.7M Q1 '18: -13.5M Q2 '18: -13.6M Q3 '18: -14.8M Q4 '18: -17.3M Q1 '19: -19.7M Q2 '19: -21.6M Q3 '19: -23.1M Q4 '19: -21.4M Q1 '20: -16.6M Q2 '20: -17.9M Q3 '20: -14M Q4 '20: -14.3M Q1 '21: -20.2M Q2 '21: -20.2M Q3 '21: -19.5M Q4 '21: -18M Q1 '22: -17.8M Q2 '22: -19.9M Q3 '22: -21.5M Q4 '22: -19.4M Q1 '23: -22.5M Q2 '23: -20.6M Q3 '23: -19.2M Q4 '23: -20.1M Q1 '24: -31.6M Q2 '24: -43.6M Q3 '24: -46M Q4 '24: -50.6M Q1 '25: -63.9M Q2 '25: -67.6M Q3 '25: -68.7M Q4 '25: -69.8M Q1 '26: -93.3M Q2 '26: -82.1M Q2 '14 Q1 '16 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q1 '13: -3.2M Q2 '13: -3.1M Q3 '13: -3.5M Q4 '13: -3.5M Q1 '14: -7M Q2 '14: -6.4M Q3 '14: -7.3M Q4 '14: -8M Q1 '15: -7.6M Q2 '15: -10M Q3 '15: -11.5M Q4 '15: -10.6M Q1 '16: -10.8M Q2 '16: -11.4M Q2 '16: -11.4M Q3 '16: -9.6M Q4 '16: -12.8M Q1 '17: -16M Q2 '17: -18.7M Q3 '17: -15.6M Q4 '17: -13.1M Q1 '18: -13.8M Q2 '18: -13.8M Q3 '18: -15M Q4 '18: -17.4M Q1 '19: -17.1M Q2 '19: -24.5M Q3 '19: -18.8M Q4 '19: -26M Q1 '20: -21.5M Q2 '20: -36.6M Q3 '20: -11.9M Q4 '20: -85.6M Q1 '21: 3.1M Q2 '21: -8.5M Q3 '21: 2.7M Q4 '21: -3.9M Q1 '22: -12.5M Q2 '22: -18.8M Q3 '22: -24.2M Q4 '22: -15.5M Q1 '23: -30.3M Q2 '23: -20.7M Q3 '23: -516K Q4 '23: -29.2M Q1 '24: -64.8M Q2 '24: -43.8M Q3 '24: -36.5M Q4 '24: -48.4M Q1 '25: -64.1M Q2 '25: -67.8M Q3 '25: -69.4M Q4 '25: -64.7M Q1 '26: -88.6M Q2 '26: -78.8M Q2 '14 Q1 '16 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue Quarterly

0 700K 1.4M 2.1M Q1 '18: 80K Q2 '18: 153K Q3 '18: 115K Q4 '18: 117K Q1 '19: 128K Q2 '19: 552K Q3 '19: 806K Q4 '19: 839K Q1 '20: 819K Q2 '20: 134K Q3 '20: 450K Q4 '20: 680K Q1 '21: 892K Q2 '21: 1.1M Q3 '21: 1.3M Q4 '21: 1.1M Q1 '22: 1.3M Q2 '22: 1.2M Q3 '22: 1.1M Q4 '22: 1M Q1 '23: 1.2M Q2 '23: 1.3M Q3 '23: 1.4M Q4 '23: 1.4M Q1 '24: 1.3M Q2 '24: 1.5M Q3 '24: 1.6M Q4 '24: 1.2M Q1 '25: 1.3M Q2 '25: 1.9M Q3 '25: 1.8M Q4 '25: 1.6M Q1 '26: 1.3M Q2 '26: 2M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '13: -2.9M Q4 '13: -3.5M Q1 '14: -4M Q2 '14: -4.5M Q3 '14: -6.3M Q4 '14: -5.6M Q1 '15: -6.9M Q2 '15: -8.5M Q3 '15: -9.7M Q4 '15: -8.6M Q1 '16: -9.3M Q2 '16: -9.8M Q3 '16: -7.3M Q4 '16: -7.6M Q1 '17: -14.6M Q2 '17: -11.1M Q3 '17: -14.4M Q4 '17: -10.4M Q1 '18: -12.5M Q2 '18: -12.2M Q3 '18: -10.9M Q4 '18: -13.6M Q1 '19: -19.4M Q2 '19: -19.2M Q3 '19: -19.5M Q4 '19: -19.5M Q1 '20: -18.9M Q2 '20: -14.8M Q3 '20: -13.7M Q4 '20: -6.2M Q1 '21: -17.4M Q2 '21: -20.1M Q3 '21: -13M Q4 '21: -15.2M Q1 '22: -18.6M Q2 '22: -10.9M Q3 '22: -13.2M Q4 '22: -17M Q1 '23: -20M Q2 '23: -20.1M Q3 '23: -7.7M Q4 '23: -22.5M Q1 '24: -33.9M Q2 '24: -24.8M Q3 '24: -36.6M Q4 '24: -39.4M Q1 '25: -44.7M Q2 '25: -55.2M Q3 '25: -50.7M Q4 '25: -54.2M Q1 '26: -66M Q2 '26: -67.3M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '13: -3M Q4 '13: -3.7M Q1 '14: -4.3M Q2 '14: -4.8M Q3 '14: -6.6M Q4 '14: -6.1M Q1 '15: -7.2M Q2 '15: -9.4M Q3 '15: -9.8M Q4 '15: -9.1M Q1 '16: -9.4M Q2 '16: -10M Q3 '16: -8.2M Q4 '16: -8.3M Q1 '17: -16.2M Q2 '17: -15.1M Q3 '17: -16.4M Q4 '17: -10.9M Q1 '18: -12.9M Q2 '18: -12.8M Q3 '18: -11.3M Q4 '18: -14.1M Q1 '19: -20.1M Q2 '19: -19.7M Q3 '19: -20M Q4 '19: -20.1M Q1 '20: -19.1M Q2 '20: -14.9M Q3 '20: -13.9M Q4 '20: -6.5M Q1 '21: -17.5M Q2 '21: -20.2M Q3 '21: -13.3M Q4 '21: -15.8M Q1 '22: -18.9M Q2 '22: -11.4M Q3 '22: -14M Q4 '22: -19.1M Q1 '23: -23.4M Q2 '23: -22.1M Q3 '23: -8M Q4 '23: -22.9M Q1 '24: -34.1M Q2 '24: -25.5M Q3 '24: -36.6M Q4 '24: -39.6M Q1 '25: -46.6M Q2 '25: -56.5M Q3 '25: -56.7M Q4 '25: -57.1M Q1 '26: -70.7M Q2 '26: -70.6M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q1 '18: 34.8M Q3 '18: 39M Q1 '19: 44.2M Q3 '19: 52.7M Q1 '20: 51.9M Q2 '20: 57.4M Q3 '20: 68.8M Q1 '21: 87.2M Q2 '21: 82.1M Q3 '21: 85.4M Q1 '22: 82.5M Q2 '22: 82.5M Q3 '22: 77M Q1 '23: 77.4M Q2 '23: 78M Q3 '23: 85.1M Q1 '24: 132M Q2 '24: 165.8M Q3 '24: 167M Q1 '25: 169.4M Q2 '25: 172.6M Q3 '25: 183.9M Q1 '26: 224.1M Q2 '26: 225M Q1 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '13: -5.11 Q1 '14: -6.30 Q2 '14: -7.21 Q3 '14: -6.35 Q4 '14: -5.40 Q1 '15: -3.30 Q2 '15: -1.65 Q3 '15: -1.64 Q4 '15: -1.70 Q1 '16: -1.79 Q2 '16: -1.80 Q1 '17: -1.95 Q2 '17: -2.13 Q3 '17: -2.28 Q4 '17: -2.20 Q1 '18: -2.02 Q2 '18: -1.75 Q3 '18: -1.59 Q4 '18: -1.57 Q1 '19: -1.62 Q2 '19: -1.82 Q3 '19: -1.89 Q4 '19: -2.00 Q1 '20: -1.96 Q2 '20: -2.03 Q3 '20: -1.79 Q4 '20: -2.60 Q3 '22: -1.01 Q4 '22: -1.02 Q1 '23: -1.19 Q2 '23: -1.20 Q3 '24: -1.22 Q4 '24: -1.25 Q1 '25: -1.14 Q2 '25: -1.27 Q3 '25: -1.43 Q4 '25: -1.42 Q1 '26: -1.44 Q2 '26: -1.40 Q3 '14 Q4 '15 Q3 '17 Q4 '18 Q1 '20 Q4 '22 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.